Caris Life Sciences (CAI) closed FY 2025 with Q4 revenue of US$292.9 million and basic EPS of US$0.29, alongside trailing 12 month revenue of US$812.0 million and a trailing basic EPS loss of US$3.22, set against a 97% year over year revenue increase and expectations for earnings to grow about 70.5% per year with profitability projected within three years. Over recent periods, the company has seen quarterly revenue move from US$101.6 million in Q3 2024 to US$129.9 million in Q4 2024, then to US$120.9 million in Q1 2025, US$181.4 million in Q2 2025, US$216.8 million in Q3 2025 and US$292.9 million in Q4 2025. Basic EPS has ranged from a loss of US$2.59 in Q3 2024 to a loss of US$1.74 in Q4 2024, a loss of US$3.57 in Q1 2025, a loss of US$7.97 in Q2 2025, US$0.09 in Q3 2025 and US$0.29 in Q4 2025, leaving investors weighing strong revenue momentum and forecast earnings growth against still negative trailing margins.

See our full analysis for Caris Life Sciences.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the widely followed growth and profitability narratives around Caris Life Sciences, and where the latest margins data starts to challenge those stories.

97% revenue growth, but TTM loss of US$538 million still looms large

• On a trailing 12 month basis, Caris generated US$812.0 million of revenue against a net loss of US$537.957 million, with Basic EPS over that period at a loss of US$3.22.
• Consensus narrative expects revenue to grow about 27.6% per year with margins moving from a loss of roughly 105.1% to 15.3% in three years. However, the current trailing loss shows that the path from US$537.957 million of red ink to the projected US$206.4 million of earnings is still wide.
  • Analysts see earnings eventually reaching US$206.4 million, which contrasts sharply with the latest trailing loss and underlines that the current numbers are far from those targets.
  • Revenue already grew 97% year over year, which lines up with the growth narrative, but the lack of established net profit margin improvement in the data means those higher sales have not yet translated into sustained profits.

Quarterly swing from US$517 million loss to US$82 million profit tests the bullish case

• Within FY 2025, quarterly net income moved from a loss of US$517.197 million in Q2 to a profit of US$81.957 million in Q4, with Basic EPS shifting from a loss of US$7.97 to a profit of US$0.29 over that span.
• Bulls argue that scaling Whole Exome and Whole Transcriptome testing plus stronger reimbursement can support earnings growth of about 70.5% per year and profitability within three years. However, the very large Q2 loss and the positive Q4 result sit side by side and highlight how dependent the story is on reimbursement, mix and spending choices.
  • The bullish view leans on rising average selling prices helped by a CMS rate of US$8,455 and commercial contracts, which is consistent with the jump in quarterly revenue from US$120.9 million in Q1 2025 to US$292.9 million in Q4. Yet the earlier US$517.197 million loss shows that higher pricing has not consistently prevented large charges.
  • Bulls also look to MRD and early detection as future earnings drivers, but with trailing 12 month net income still a loss of US$537.957 million, the numbers so far mainly indicate that growth projects are costly before they are fully commercialized.

Bulls point to strong revenue momentum and expected margin improvement, but the jump from a US$517 million quarterly loss to profitability is exactly why many want to understand the optimistic case in more detail before leaning in. 🐂 Caris Life Sciences Bull Case

DCF gap and 6.9x P/S contrast with ongoing unprofitability for bears

• The stock trades around US$19.84 against a DCF fair value of about US$39.99, while the P/S ratio of 6.9x sits above the peer average of 4.7x and below the wider US biotech group at 10.9x.
• Bears highlight that the company is still loss making over the trailing 12 months and question whether a 6.9x P/S is justified when net profit margin has not yet moved into positive territory, even though an analyst price target of 29.69 implies upside from the current share price.
  • The trailing loss of US$537.957 million and Basic EPS loss of US$3.22 support the cautious view that profitability is not yet established despite the apparent discount to DCF fair value.
  • At the same time, the 97% revenue growth and forecasts for revenue to grow about 15.7% per year versus 11.4% for the US market help explain why some investors are still willing to pay a higher P/S than peers even while the business is unprofitable.

Skeptics focus on the mix of rapid growth, a large trailing loss and a premium P/S, which makes the more cautious earnings path and valuation argument worth reading in full before drawing a conclusion. 🐻 Caris Life Sciences Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Caris Life Sciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the combination of strong growth and significant losses leaves you uncertain, now is a good time to review the numbers yourself and decide where you stand. To better understand the potential advantages, take a closer look at the 3 key rewards

See What Else Is Out There

Caris Life Sciences combines rapid revenue growth with a trailing net loss of US$537.957 million and uneven quarterly earnings, which keeps overall risk elevated.

If you want ideas that put more weight on stability and capital preservation, check out the 72 resilient stocks with low risk scores today and compare those profiles against this kind of volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.